

# CIMTECH PTY LTD

## TRANSLATING TRADITIONAL MEDICINE

### NOVEL SKIN, WOUND HEALING AND BONE GROWTH PLATFORMS



Bridging the gap between research, commercialisation, and investors.



#### SUMMARY OF THE OPPORTUNITY

Traditional Maori medicine has been passed from generation to generation and until recently, knowledge of these healing remedies was presumed to be lost. Dr Graham Matheson has identified a number of plants and plant extracts that were found to be efficacious in a number of clinical indications including bone growth, wound healing, dermatology and hair (re)growth. Dr Matheson has formed CIMTECH Pty Ltd to commercialise these new discoveries.

#### THE FOCUS


CIMTECH's core strategy is to target the greater than \$25bn bone development market with an emphasis in bone fracture, spinal fusion and osteoporosis: large markets where there is an unmet medical need for novel and effective solutions. CIMTECH will develop these clinical assets in bone-growth internally and pursue partnering opportunities to accelerate, improve and maximise commercialisation of pre-clinical candidates in wound healing, cosmetics/skin rejuvenation, hair growth and veterinary applications.

CIMTECH will follow a dual development strategy consisting of a pharmaceutical development program (based on identifying a drug like molecule) and a complementary medicine development program (based on the use of plant extracts).


#### PROOF OF CONCEPT STUDIES

CIMTECH has already demonstrated proof-of-concept in osteoporosis animal models and is in the process of identifying the active molecule involved in rapid bone repair. Initial bone development studies have increased the cellular response to bone injury through cartilage formation and new bone formation from the cartilaginous cap. This has been shown to occur in fractures, defects and bone grafts, and the effect is seen at one week, 3 weeks, 6 weeks and 8 weeks. This is demonstrable in aged oestrogen deficient bone, normal aged bones and young healthy bones. This is a platform technology with potential applications spanning the orthopaedic, prosthesis, osteoporosis, rheumatology and sports medicine specialties with numerous clinical platforms in which this technology could be of significant benefit.

**Bone regeneration was assessed in a non-healing model, a 20mm ulna defect in rabbits at one week, which should not heal. This one week time-point provides a view to the alteration of bone healing physiology in the early stages**



The Australian Research Network is a consulting company focused on emerging Australian technologies.



#### Clinical Applications

- Clinically challenging scenarios
- Non union
  - Complex Fractures
  - Stress Fractures
  - Grafting
- Complex Fractures without operative options
- Developing countries
  - High anaesthetic risk patients

#### Clinical Value

- Driving forces for demand are increasing
- Increasing arthritis and degenerative joints
  - Increasing obesity
  - Increasing osteoporosis
  - Increasing expectations of level of activity into retirement
  - Aging populations in Japan, USA, Europe
  - Increasing market access and expectations of BRIC countries

#### Clinical Advantage

- Systemic Therapeutic
- Surgeons do not need to change their current surgical preferences
  - Non-invasive treatment
- Non-Protein Drug
- Low cost to manufacture
  - Temperature stable (0-100 °C)
  - No foreign proteins or DNA
  - Less likely to induce immunogenic response

#### Market Advantage

- Expected to be first in class therapeutic
- Cost effective
- Clear market opportunities
- Potential for additional applications in arthritis, osteoporosis, soft tissue - bone interface
- Potential for mechanism of action to enlighten new rational drug design

#### INTELLECTUAL PROPERTY

On-going development of the technology has created a patent portfolio that currently includes four patents two in PCT and two provisionals.

#### OPPORTUNITY

This technology represents a new frontier in the treatment of bone growth, wounds and skin disorders and hair growth. The technology described requires co-development with partners with demonstrated ability to take such new products through clinical trials and into the market. Development, marketing and distribution partner are sought in both the animal and human healthcare markets.

#### ABOUT TM VENTURES AND THE AUSTRALIAN RESEARCH NETWORK

From the Black Box Flight Recorder to Google Maps, Australia's innovation system is transforming the world we live in. CSL's anti-cancer vaccine (Gardasil), Biota's flu treatment (Relenza) and Cochlear's Bionic Ear are but a handful of medical technologies that were born of Aussie talent.

The Australian Research Network is a boutique consulting and business development company focused on emerging Australian innovation. The Network is committed to maximizing the value of technologies for both our domestic and international clients and if your company is considering Australian investment opportunities, contact us.

#### FOR FURTHER INFORMATION:

Tony Romagnino  
Managing Director  
Australian Research Network  
T +1-514-247-8383  
tony@australianresearchnetwork.com  
www.australianresearchnetwork.com



Dr Matt Harris  
Managing Director  
TM Ventures  
T +61 (0)439-620-125  
mharris@tmventures.com.au  
www.tmventures.com.au

